TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07189065: An Open-Label, Randomized Controlled, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Rocbrutinib Monotherapy Versus Investigator's Choice of Therapy in Patients With Relapsed or Refractory No

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07189065 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07189065 Rescue Dossier →